Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H1 2015

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H1 2015', provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Recurrent Head And Neck Cancer Squamous Cell Carcinoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview 8

Therapeutics Development 9

Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Overview 9

Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Comparative Analysis 10

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Therapeutics under Development by Companies 11

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Products under Development by Companies 16

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Companies Involved in Therapeutics Development 18

Advaxis, Inc. 18

Amgen Inc. 19

AVEO Pharmaceuticals, Inc. 20

Critical Outcome Technologies Inc. 21

Daiichi Sankyo Company, Limited 22

Genentech, Inc. 23

Glycotope GmbH 24

Immunovative Therapies, Ltd. 25

Laboratoires Pierre Fabre SA 26

Mabion SA 27

MedImmune, LLC 28

Merck & Co., Inc. 29

Novartis AG 30

Oncolytics Biotech Inc. 31

Ono Pharmaceutical Co., Ltd. 32

Panacea Biotec Limited 33

PCI Biotech AS 34

Shionogi & Co., Ltd. 35

Symphogen A/S 36

VentiRx Pharmaceuticals, Inc. 37

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Combination Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

ADXS-HPV-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

AlloVax-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

alpelisib-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

bleomycin sulfate-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

cetuximab biobetter-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

cetuximab biosimilar-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

cetuximab biosimilar-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

cetuximab biosimilar-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

COTI-2-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

duligotuzumab-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

durvalumab-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

durvalumab + tremelimumab-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

ficlatuzumab-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

futuximab-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

LJM-716-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

motolimod-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

nivolumab-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

patritumab-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

pelareorep-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

pembrolizumab-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

S-488210-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

vinflunine ditartrate-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Recent Pipeline Updates 98

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Dormant Projects 137

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Discontinued Products 138

Appendix 139

Methodology 139

Coverage 139

Secondary Research 139

Primary Research 139

Expert Panel Validation 139

Contact Us 139

Disclaimer 140

List of Tables

Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H1 2015 9

Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Development by Companies, H1 2015 (Contd..1) 17

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Advaxis, Inc., H1 2015 18

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Amgen Inc., H1 2015 19

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 20

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Critical Outcome Technologies Inc., H1 2015 21

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 22

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Genentech, Inc., H1 2015 23

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Glycotope GmbH, H1 2015 24

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Immunovative Therapies, Ltd., H1 2015 25

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 26

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Mabion SA, H1 2015 27

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by MedImmune, LLC, H1 2015 28

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Merck & Co., Inc., H1 2015 29

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Novartis AG, H1 2015 30

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Oncolytics Biotech Inc., H1 2015 31

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 32

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Panacea Biotec Limited, H1 2015 33

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by PCI Biotech AS, H1 2015 34

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Shionogi & Co., Ltd., H1 2015 35

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Symphogen A/S, H1 2015 36

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 37

Assessment by Monotherapy Products, H1 2015 38

Assessment by Combination Products, H1 2015 39

Number of Products by Stage and Target, H1 2015 41

Number of Products by Stage and Mechanism of Action, H1 2015 43

Number of Products by Stage and Route of Administration, H1 2015 45

Number of Products by Stage and Molecule Type, H1 2015 47

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics-Recent Pipeline Updates, H1 2015 98

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Dormant Projects, H1 2015 137

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Discontinued Products, H1 2015 138

List of Figures

Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H1 2015 9

Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 14

Assessment by Monotherapy Products, H1 2015 38

Number of Products by Top 10 Targets, H1 2015 40

Number of Products by Stage and Top 10 Targets, H1 2015 41

Number of Products by Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Top 10 Routes of Administration, H1 2015 44

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 45

Number of Products by Top 10 Molecule Types, H1 2015 46

Number of Products by Stage and Top 10 Molecule Types, H1 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advaxis, Inc.

Amgen Inc.

AVEO Pharmaceuticals, Inc.

Critical Outcome Technologies Inc.

Daiichi Sankyo Company, Limited

Genentech, Inc.

Glycotope GmbH

Immunovative Therapies, Ltd.

Laboratoires Pierre Fabre SA

Mabion SA

MedImmune, LLC

Merck & Co., Inc.

Novartis AG

Oncolytics Biotech Inc.

Ono Pharmaceutical Co., Ltd.

Panacea Biotec Limited

PCI Biotech AS

Shionogi & Co., Ltd.

Symphogen A/S

VentiRx Pharmaceuticals, Inc.

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutic Products under Development, Key Players in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Overview, Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline, Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com